参考文献/References:
[1] 刘明波,何新叶,杨晓红,等. 《中国心血管健康与疾病报告2023》要点解读[J]. 中国全科医学,2025,28(1):20-38.
[2] Khan MS,Shahid I,Bennis A,et al. Global epidemiology of heart failure[J]. Nat Rev Cardiol,2024,21(10):717-734.
[3] Pieroni M,Zocchi C,Ciabatti M. Cardiac involvement in Fabry disease:Recent advances,unresolved issues,and unmet needs[J]. Eur Heart J Suppl,2025,27(suppl 1):i51-i55.
[4] 中国医师协会心力衰竭专业委员会,国家心血管病专家委员会心力衰竭专业委员会,中华心力衰竭和心肌病杂志编辑委员会. 心力衰竭生物标志物临床应用中国专家共识[J]. 中华心力衰竭和心肌病杂志,2022,6(3):175-192.
[5] Singh G,Bamba H,Inban P,et al. The role of biomarkers in the prognosis and risk stratification in heart failure:a systematic review[J]. Dis Mon,2024,70(10):101782.
[6] 罗年桑,张海峰,刘品明,等. 血清可溶性ST2联合白细胞介素-33对射血分数保留的心力衰竭辅助诊断价值的初探[J]. 中华心血管病杂志,2017,45(3):198-203.
[7] Pusceddu I,Dieplinger B,Mueller T. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans[J]. Clin Chim Acta,2019,495:493-500.
[8] Homsak E,Gruson D. Soluble ST2:a complex and diverse role in several diseases[J]. Clin Chim Acta,2020,507:75-87.
[9] Lotierzo M,Dupuy AM,Kalmanovich E,et al. sST2 as a value-added biomarker in heart failure[J]. Clin Chim Acta,2020,501:120-130.
[10] Zhang T,Xu C,Zhao R,et al. Diagnostic value of sST2 in cardiovascular diseases:a systematic review and meta-analysis[J]. Front Cardiovasc Med,2021,8:697837.
[11] Wei P,Liu L,Wang X,et al. Expression of soluble ST2 in patients with essential hypertension and its relationship with left ventricular hypertrophy[J]. ESC Heart Fail,2023,10(1):303-310.
[12] Natorska J,Z?bczyk M,Undas A. Neutrophil extracellular traps (NETs) in cardiovascular diseases:from molecular mechanisms to therapeutic interventions[J]. Kardiol Pol,2023,81(12):1205-1216.
[13] Li B,Dowley M,Langley S,et al. The mortality implications of increasing and decreasing sST2 levels during acute decompensated heart failure[J]. Eur Heart J,2024,45(suppl 1):ehae666.976.
[14] Cao ZQ,Yu X,Leng P. Research progress on the role of gal-3 in cardio/cerebrovascular diseases[J]. Biomed Pharmacother,2021,133:111066.
[15] Echouffo-Tcheugui JB,Zhang S,Florido R,et al. Galectin-3,metabolic risk,and incident heart failure:the ARIC study[J]. J Am Heart Assoc,2024,13(6):e031607.
[16] Vlachou F,Varela A,Stathopoulou K,et al. Galectin-3 interferes with tissue repair and promotes cardiac dysfunction and comorbidities in a genetic heart failure model[J]. Cell Mol Life Sci,2022,79(5):250.
[17] Berezin AE,Berezin AA. Biomarkers in heart failure:from research to clinical practice[J]. Ann Lab Med,2023,43(3):225-236.
[18] Hara A,Niwa M,Kanayama T,et al. Galectin-3:a potential prognostic and diagnostic marker for heart disease and detection of early stage pathology[J]. Biomolecules,2020,10(9):1277.
[19] Trippel TD,Mende M,Düngen HD,et al. The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction:results from the DIAST-CHF study[J]. ESC Heart Fail,2021,8(2):829-841.
[20] Zaborska B,Sikora-Fr?c M,Smar? K,et al. The role of galectin-3 in heart failure-the diagnostic,prognostic and therapeutic potential-where do we stand?[J]. Int J Mol Sci,2023,24(17):13111.
[21] Lau ES,Liu E,Paniagua SM,et al. Galectin-3 inhibition with modified citrus pectin in hypertension[J]. JACC Basic Transl Sci,2021,6(1):12-21.
[22] Schwarz A,Kinscherf R,Bonaterra GA. Role of the stress- and inflammation-induced cytokine GDF-15 in cardiovascular diseases:from basic research to clinical relevance[J]. Rev Cardiovasc Med,2023,24(3):81.
[23] Myrmel GMS,Steiro OT,Tjora HL,et al. Growth differentiation factor 15:a prognostic marker in patients with acute chest pain without acute myocardial infarction[J]. Clin Chem,2023,69(6):649-660.
[24] Silva-Bermudez LS,Klüter H,Kzhyshkowska JG. Macrophages as a source and target of GDF-15[J]. Int J Mol Sci,2024,25(13):7313.
[25] Rochette L,Dogon G,Zeller M,et al. GDF15 and cardiac cells:current concepts and new insights[J]. Int J Mol Sci,2021,22(16):8889.
[26] Kosum P,Siranart N,Mattanapojanat N,et al. GDF-15:a novel biomarker of heart failure predicts short-term and long-term heart-failure rehospitalization and short-term mortality in patients with acute heart failure syndrome[J]. BMC Cardiovasc Disord,2024,24(1):151.
[27] Ueland T,Gullestad L,Kou L,et al. Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia:results from RED-HF[J]. Clin Res Cardiol,2022,111(4):440-450.
[28] Lyu L,Xu J,Xv C,et al. Prognostic value of growth differentiation factor-15 in heart failure among whole ejection fraction phenotypes[J]. ESC Heart Fail,2024,11(4):2295-2304.
[29] Farag NM,Mousa M,Elsayed E,et al. GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease[J]. Ital J Pediatr,2023,49(1):106.
[30] Marsche G,Stadler JT,Kargl J,et al. Understanding myeloperoxidase-induced damage to HDL structure and function in the vessel wall:implications for HDL-based therapies[J]. Antioxidants (Basel),2022,11(3):556.
[31] Reichlin T,Socrates T,Egli P,et al. Use of myeloperoxidase for risk stratification in acute heart failure[J]. Clin Chem,2010,56(6):944-951.
[32] Geissen S,Braumann S,Adler J,et al. Treatment of left ventricular dysfunction in dilated cardiomyopathy with a myeloperoxidase inhibitor[J]. medRxiv,2022.DOI:https://doi.org/10.1101/2022.11.02.22281785
[33] Chaikijurajai T,Tang WHW. Reappraisal of inflammatory biomarkers in heart failure[J]. Curr Heart Fail Rep,2020,17(1):9-19.
[34] Erdo?an SB,Sel?uk ?N,Ba?top?u M,et al. Critical limb ischemia patients clinically improving with medical treatment have lower neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios[J]. Vascular,2021,29(6):920-926.
[35] Delcea C,Adrian Buzea C,Dobrev D,et al. Prognostic roles of neutrophil-lymphocyte,monocyte-lymphocyte and platelet-lymphocyte ratios for long-term all-cause mortality in heart failure[J]. Int J Cardiol Heart Vasc,2024,54:101502.
[36] Zhang Q,Si D,Zhang Z,et al. Value of the platelet-to-lymphocyte ratio in the prediction of left ventricular thrombus in anterior ST-elevation myocardial infarction with left ventricular dysfunction[J]. BMC Cardiovasc Disord,2020,20(1):428.
[37] Chen W,Xin S,Xu B. Value research of NLR,PLR,and RDW in prognostic assessment of patients with colorectal cancer[J]. J Healthc Eng,2022,2022:7971415.
[38] Zahorec R. Neutrophil-to-lymphocyte ratio,past,present and future perspectives[J]. Bratisl Lek Listy,2021,122(7):474-488.
[39] Chilton PM,Embry CA,Mitchell TC. Effects of differences in lipid A structure on TLR4 pro-inflammatory signaling and inflammasome activation[J]. Front Immunol,2012,3:154.
[40] Wang R,Wu J,Ye H,et al. Application value of systemic inflammatory indexes in the clinical evaluation of patients with heart failure with preserved ejection fraction (HFpEF)[J]. Medicina (Kaunas),2022,58(10):1473.
[41] 魏亚君,侯泽,刘雨庭,等. 单核细胞与高密度脂蛋白胆固醇比值评估射血分数降低型心力衰竭患者的预后价值[J]. 中华预防医学杂志,2025,59(3):309-316.
[42] Amezcua-Castillo E,González-Pacheco H,Sáenz-San Martín A,et al. C-reactive protein:the quintessential marker of systemic inflammation in coronary artery disease-Advancing toward precision medicine[J]. Biomedicines,2023,11(9):2444.
[43] Erd?l MA,Yayla KG. Relationship between C-reactive protein to albumin ratio and coronary artery calcium score and CAD-RADS scores with coronary computed tomography angiography[J]. Turk J Med Sci,2021,51(5):2674-2682.
[44] Karaba? Y,?a?da? M,Rencuzogullari I,et al. Usefulness of the C-reactive protein/albumin ratio for predicting no-reflow in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention[J]. Eur J Clin Invest,2018,48(6):e12928.
[45] Ye M,Yu G,Han F,et al. Non-linear association of CAR with all-cause and cardiovascular mortality in coronary heart disease:a retrospective cohort study from NHANES[J]. Clin Appl Thromb Hemost,2024,30:10760296241271382.
[46] Li J,Man Q,Wang Y,et al. The metabolic vulnerability index as a novel tool for mortality risk stratification in a large-scale population-based cohort[J]. Redox Biol,2025,81:103585.
[47] Kumar S,Conners KM,Shearer JJ,et al. Frailty and metabolic vulnerability in heart failure:a community cohort study[J]. J Am Heart Assoc,2024,13(8):e031616.
[48] Kuku KO,Shearer JJ,Joo J,et al. Cross-sectional evaluation of the metabolic vulnerability index in heart failure populations[J]. BMC Cardiovasc Disord,2025,25(1):292.
相似文献/References:
[1]郭君君,郑宏超,曹阳.生物标志物对急性心肌梗死介入治疗预后的预测意义[J].心血管病学进展,2016,(1):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
GUO Junjun,ZHENG Hongchao,CAO Yang.Prognostic Significance of Biomarkers in Predicting Acute Myocardial
Infarction after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2016,(10):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
[2]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(10):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[3]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(10):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[4]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(10):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[5]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(10):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[6]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(10):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[7]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(10):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[8]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(10):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[9]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(10):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[10]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(10):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[11]刘壮壮 黄宇理.心力衰竭生物标志物的研究进展[J].心血管病学进展,2020,(1):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
LIU Zhuangzhuang,HUANG Yuli.Biomarkers for Heart Failure[J].Advances in Cardiovascular Diseases,2020,(10):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
[12]王同霞 陈章荣.可溶ST2与心力衰竭患者预后的评价[J].心血管病学进展,2020,(5):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
WANG Tongxia,CHEN Zhangrong.Prognosis of Heart Failure Patients and Soluble ST2[J].Advances in Cardiovascular Diseases,2020,(10):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
[13]孙悦宁 富路.左心室逆重构在心力衰竭中的研究新进展[J].心血管病学进展,2021,(6):525.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.012]
SUN Yuening,FU Lu.Research Progress of Left Ventricular Reverse Remodeling in Heart Failure[J].Advances in Cardiovascular Diseases,2021,(10):525.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.012]
[14]魏天天?王学超?吴海波?杜荣品.心力衰竭生物标志物的研究进展[J].心血管病学进展,2021,(7):610.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.009]
WEI Tiantian,WANG Xuechao,WU Haibo,et al.Biomarkers of Heart Failure[J].Advances in Cardiovascular Diseases,2021,(10):610.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.009]